[1]侯文哲,刘时华,田志刚,等.川芎嗪联合瑞舒伐他汀对缺血性脑白质病变患者的保护作用[J].医学信息,2021,34(17):147-150.[doi:10.3969/j.issn.1006-1959.2021.17.039]
 HOU Wen-zhe,LIU Shi-hua,TIAN Zhi-gang,et al.The Protective Effect of Ligustrazine Combined with Rosuvastatin on Patients with Ischemic Leukoencephalopathy[J].Medical Information,2021,34(17):147-150.[doi:10.3969/j.issn.1006-1959.2021.17.039]
点击复制

川芎嗪联合瑞舒伐他汀对缺血性脑白质病变患者的保护作用()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年17期
页码:
147-150
栏目:
药物与临床
出版日期:
2021-09-01

文章信息/Info

Title:
The Protective Effect of Ligustrazine Combined with Rosuvastatin on Patients with Ischemic Leukoencephalopathy
文章编号:
1006-1959(2021)17-0147-04
作者:
侯文哲刘时华田志刚
(安徽医科大学附属宿州医院神经内科,安徽 宿州 234000)
Author(s):
HOU Wen-zheLIU Shi-huaTIAN Zhi-ganget al.
(Department of Neurology,Suzhou Hospital Affiliated to Anhui Medical University,Suzhou 234000,Anhui,China)
关键词:
缺血性脑白质病变血脑屏障川芎嗪瑞舒伐他汀
Keywords:
White matter ischemic lesionBlood-brain barrierLigustrazineRosuvastatin
分类号:
R741
DOI:
10.3969/j.issn.1006-1959.2021.17.039
文献标志码:
A
摘要:
目的 探讨川芎嗪联合瑞舒伐他汀治疗的缺血性脑白质病变(WMIL)患者血清中基质金属蛋白酶3(MMP3)、基质金属蛋白酶9(MMP9)、胶质纤维酸性蛋白(GFAP)及生化指标水平,探索联合用药对WMIL的潜在保护作用。方法 选取2019年5月-2020年10月我院收治的并明确诊断为WMIL患者122例,将其随机分为对照组和实验组,各61例。所有患者均予以常规治疗,对照组在此基础上加用瑞舒伐他汀,实验组在对照组的基础上加用川芎嗪,比较两组血清MMP3、MMP9、GFAP、同型半胱氨酸、胱抑素C、超敏C反应蛋白、甘油三酯及胆固醇水平的差异。结果 两组MMP3、MMP9、GFAP、同型半胱氨酸、超敏C反应蛋白、甘油三酯、胆固醇水平均较治疗前降低,差异有统计学意义(P<0.05);同时,实验组MMP3、MMP9、GFAP、同型半胱氨酸、超敏C反应蛋白水平低于对照组,差异有统计学意义(P<0.05)。结论 川芎嗪联合瑞舒伐他汀治疗WMIL能够有效降低患者血清MMP3、MMP9、GFAP、同型半胱氨酸、超敏C反应蛋白水平,减轻炎症反应,有利于保护缺血受损的脑白质。
Abstract:
Objective To investigate the serum levels of matrix metalloproteinase 3 (MMP3), matrix metalloproteinase 9 (MMP9), glial fibrillary acidic protein (GFAP) and biochemical indexes in patients with ischemic white matter disease (WMIL) treated with ligustrazine combined with rosuvastatin level, explore the potential protective effect of combination drugs on WMIL.Methods A total of 122 patients who were admitted to our hospital from May 2019 to October 2020 and were clearly diagnosed as WMIL were randomly divided into a control group and an experimental group, each with 61 cases.All patients were given conventional treatment. The control group was given rosuvastatin on this basis, and the experimental group was given ligustrazine on the basis of the control group.The differences in serum levels of MMP3, MMP9, GFAP, homocysteine, cystatin C, high-sensitivity C-reactive protein, triglycerides and cholesterol were compared between the two groups.Results The levels of MMP3, MMP9, GFAP, homocysteine, high-sensitivity C-reactive protein, triglycerides, and cholesterol levels in the two groups were lower than before treatment,the difference was statistically significant (P<0.05);At the same time, the levels of MMP3, MMP9, GFAP, homocysteine, and high-sensitivity C-reactive protein in the experimental group were lower than those in the control group,the difference was statistically significant (P<0.05).Conclusion The combination of ligustrazine and rosuvastatin in the treatment of WMIL can effectively reduce the serum levels of MMP3, MMP9, GFAP, homocysteine, and high-sensitivity C-reactive protein, reduce inflammation, and protect the ischemic-damaged white matter.

参考文献/References:

[1]Honnedevasthana AH,Connelly A,Smith RE.Characterisation of white matter asymmetries in the healthy human brain using diffusion MRI fixel-based analysis[J].NeuroImage,2021,225(1):117505. [2]Lu D.Beneficial role of rosuvastatin in blood-brain barrier damage following experimental ischemic stroke[J].Front Pharmacol,2018,9(2):926. [3]Tan F.Ligustrazine reduces blood-brain barrier permeability in a rat model of focal cerebral ischemia and reperfusion[J].Exp Ther Med,2015,9(5):1757-1762. [4]Carass A.Evaluating white matter lesion segmentations with refined sorensen-dice analysis[J].Sci Rep,2020,10(1):8242. [5]Brown RB.Do cerebral small vessel disease and multiple sclerosis share common Mechanisms of White Matter Injury[J].Stroke,2019,50(8):1968-1972. [6]Abdullahi W.Blood-brain barrier dysfunction in ischemic stroke:targeting tight junctions and transporters for vascular protection[J].Am J Physiol Cell Physiol,2018,315(3):343-356. [7]Rempe RG.Matrix metalloproteinases in the brain and blood-brain barrier:Versatile breakers and makers[J].Cereb Blood Flow Metab,2016,36(9):1481-1507. [8]Bruce M.Acute peripheral immune activation alters cytokine expression and glial activation in the early postnatal rat brain[J].Neuroinflammation,2019,16(1):200. [9]Beroun A.MMPs in learning and memory and neuropsychiatric disorders[J].Cell Mol Life Sci,2019,76(16):3207-3228. [10]Krishnaswamy VR.Demystifying the extracellular matrix and its proteolytic remodeling in the brain:structural and functional insights[J].Cell Mol Life Sci,2019,76(16):3229-3248. [11]Takahashi Y.A single nucleotide polymorphism(-250 A/C)of the GFAP gene is associated with brain structures and cerebral blood flow[J].Psychiatry Clin Neurosci,2020,74(1):49-55. [12]Huang J.Blood-brain barrier damage as the starting point of leukoaraiosis caused by cerebral chronic hypoperfusion and its involved mechanisms:effect of agrin and aquaporin-4[J].Biomed Res Int,2018(2018):2321797. [13]Shao Z.Tetramethylpyrazine protects neurons from oxygen-glucose deprivation-induced death[J].Med Sci Monit,2017(23):5277-5282. [14]Gong X.Tetramethylpyrazine prevents contrast-induced nephropathy via modulating tubular cell mitophagy and suppressing mitochondrial fragmentation,CCL2/CCR2-mediated inflammation, and intestinal injury[J].Oxid Med Cell Longev,2019(2019):7096912. [15]Xu SH.Tetramethylpyrazine-2’-O-sodium ferulate attenuates blood-brain barrier disruption and brain oedema after cerebral ischemia/reperfusion[J].Hum Exp Toxicol,2017,36(7):670-680. [16]Strandberg TE.Role of statin therapy in primary prevention of cardiovascular disease in elderly patients[J].Curr Atheroscler Rep,2019,21(8):28. [17]Brzica H.Sex-specific differences in organic anion transporting polypeptide 1a4(Oatp1a4) functional expression at the blood-brain barrier in Sprague-Dawley rats[J].Fluids Barriers CNS,2018,15(1):25. [18]Wang S.Atorvastatin attenuates cognitive deficits and neuroinflammation induced by abeta1-42 involving modulation of TLR4/TRAF6/NF-kappaB pathway[J].Mol Neurosci,2018,64(3):363-373.

相似文献/References:

[1]陈 莹,舒崖清,胡学强,等.血清转氨酶水平与多发性硬化患者血脑屏障破坏的相关性研究[J].医学信息,2019,32(06):105.[doi:10.3969/j.issn.1006-1959.2019.06.032]
 CHEN Ying,SHU Ya-qing,HU Xue-qiang,et al.Correlation between Serum Transaminase Levels and Blood-brain Barrier Disruption in Patients with Multiple Sclerosis[J].Medical Information,2019,32(17):105.[doi:10.3969/j.issn.1006-1959.2019.06.032]
[2]龚 晨,申潇竹,包勤文.25(OH)D水平与高龄缺血性脑白质病变的关系[J].医学信息,2022,35(01):137.[doi:10.3969/j.issn.1006-1959.2022.01.033]
 GONG Chen,SHEN Xiao-zhu,BAO Qin-wen.Relationship Between Serum 25(OH)D Level and White Matter Ischemic Lesions in Elderly Patients[J].Medical Information,2022,35(17):137.[doi:10.3969/j.issn.1006-1959.2022.01.033]
[3]陈湘姣,杨 豪,梁 辉.右美托咪定对大鼠蛛网膜下腔出血后早期脑损伤的影响[J].医学信息,2022,35(23):61.[doi:10.3969/j.issn.1006-1959.2022.23.010]
 CHEN Xiang-jiao,YANG Hao,LIANG Hui.Effect of Dexmedetomidine on Early Brain Injury After Subarachnoid Hemorrhage in Rats[J].Medical Information,2022,35(17):61.[doi:10.3969/j.issn.1006-1959.2022.23.010]
[4]张茜敏,庄璐璐,黄 嵘.乳腺癌脑转移机制、诊疗及预后的研究[J].医学信息,2023,36(03):185.[doi:10.3969/j.issn.1006-1959.2023.03.041]
 ZHANG Xi-min,ZHUANG Lu-lu,HUANG Rong.Study on the Mechanism, Diagnosis, Treatment and Prognosis of Breast Cancer Brain Metastasis[J].Medical Information,2023,36(17):185.[doi:10.3969/j.issn.1006-1959.2023.03.041]
[5]王泊浩,杨 寒,张海龙,等.姜黄素治疗蛛网膜下腔出血的研究进展[J].医学信息,2023,36(17):184.[doi:10.3969/j.issn.1006-1959.2023.17.040]
 WANG Bo-hao,YANG Han,ZHANG Hai-long,et al.Research Progress of Curcumin in the Treatment of Subarachnoid Hemorrhage[J].Medical Information,2023,36(17):184.[doi:10.3969/j.issn.1006-1959.2023.17.040]

更新日期/Last Update: 1900-01-01